Palikhe Sailesh, Ohashi Wakana, Sakamoto Takuya, Hattori Kohshi, Kawakami Masaaki, Andoh Tsugunobu, Yamazaki Hiromi, Hattori Yuichi
Department of Molecular and Medical Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
Front Pharmacol. 2019 Feb 4;10:59. doi: 10.3389/fphar.2019.00059. eCollection 2019.
G protein-coupled receptor kinase 2 (GRK2) is a ubiquitous member of the GRK family that restrains cellular activation by G protein-coupled receptor (GPCR) phosphorylation leading to receptor desensitization and internalization, but has been identified to regulate a variety of signaling molecules, among which may be associated with inflammation. In this study, we attempted to establish the regulatory role of GRK2 in the Toll-like receptor (TLR) signaling pathway for inducible nitric oxide synthase (iNOS) expression in microglial cells. When mouse MG6 cells were stimulated with the TLR4 ligands lipopolysaccharide (LPS) and paclitaxel, we found that interferon regulatory factor 1 (IRF1) protein expression and activation was upregulated, transcription of interferon-β (IFN-β) was accelerated, induction/activation of STAT1 and activation of STAT3 were promoted, and subsequently iNOS expression was upregulated. The ablation of GRK2 by small interfering RNAs (siRNAs) not only eliminated TLR4-mediated upregulation of IRF1 protein expression and nuclear translocation but also suppressed the activation of the STAT pathway, resulting in negating the iNOS upregulation. The TLR3-mediated changes in IRF1 and STAT1/3, leading to iNOS induction, were also abrogated by siRNA knockdown of GRK2. Furthermore, transfection of GRK2 siRNA blocked the exogenous IFN-β supplementation-induced increases in phosphorylation of STAT1 as well as STAT3 and abrogated the augmentation of iNOS expression in the presence of exogenous IFN-β. Taken together, our results show that GRK2 regulates the activation of IRF1 as well as the activation of the STAT pathway, leading to upregulated transcription of iNOS in activated microglial cells. Modulation of the TLR signaling pathway via GRK2 in microglia may be a novel therapeutic target for treatment of neuroinflammatory disorders.
G蛋白偶联受体激酶2(GRK2)是GRK家族中一种普遍存在的成员,它通过G蛋白偶联受体(GPCR)磷酸化来抑制细胞活化,导致受体脱敏和内化,但已被确定可调节多种信号分子,其中可能与炎症相关。在本研究中,我们试图确定GRK2在小胶质细胞中诱导型一氧化氮合酶(iNOS)表达的Toll样受体(TLR)信号通路中的调节作用。当用TLR4配体脂多糖(LPS)和紫杉醇刺激小鼠MG6细胞时,我们发现干扰素调节因子1(IRF1)蛋白表达和活化上调,干扰素-β(IFN-β)转录加速,STAT1的诱导/活化和STAT3的活化得到促进,随后iNOS表达上调。小干扰RNA(siRNA)介导的GRK2缺失不仅消除了TLR4介导的IRF1蛋白表达上调和核转位,还抑制了STAT通路的活化,导致iNOS上调被消除。GRK2的siRNA敲低也消除了TLR3介导的IRF1和STAT1/3变化,导致iNOS诱导。此外,GRK2 siRNA转染阻断了外源性IFN-β补充诱导的STAT1以及STAT3磷酸化增加,并消除了外源性IFN-β存在下iNOS表达的增加。综上所述,我们的结果表明,GRK2调节IRF1的活化以及STAT通路的活化,导致活化的小胶质细胞中iNOS转录上调。通过GRK2调节小胶质细胞中的TLR信号通路可能是治疗神经炎症性疾病的新治疗靶点。